TMDX · All filings · Read this filing
What changed 10-K
Item 5. Market for Registrant’s Common Equity
2022-03-01 compared with 2021-03-11 · 1 added, 1 removed, 26 unchanged (7% of the section changed)
15 unchanged sentences
None of the net proceeds were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10.0% or more of any class of our equity securities or to any other affiliates, other than payments in the ordinary course of business to officers for salaries and to non-employee directors as compensation for board or board committee service.
−Removed: As of December 31, 2020, we estimate that we have used approximately $47.4 million of the net proceeds from our IPO for commercialization of OCS Lung, research and development, and general corporate purposes.
+Added: As of December 31, 2021, we estimate that we have used approximately $80.6 million of the net proceeds from our IPO for commercialization of our OCS products, research and development, and general corporate purposes.
We are holding a significant portion of the remaining net proceeds in money market funds, U.S.
9 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.